Invega Sustenna (paliperidone palmitate extended-release injectable suspension) received FDA approval on September 25, 2009 [1]. This long-acting injectable antipsychotic is used for the treatment of schizophrenia in adults [2].
When does Invega Sustenna's patent expire?
The patent exclusivity for Invega Sustenna has faced challenges and expired in various regions. For detailed information on patent expiry dates, including any ongoing litigation or extensions, DrugPatentWatch.com can be a valuable resource [3].
How does Invega Sustenna work?
Invega Sustenna is a long-acting injectable form of paliperidone, which is the active metabolite of risperidone. Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. This action is believed to help reduce the symptoms of schizophrenia, such as hallucinations, delusions, and disorganized thinking [4].
Are there other long-acting injectable antipsychotics?
Yes, several other long-acting injectable antipsychotics are available. These include medications like Risperdal Consta (risperidone), Abilify Maintena (aripiprazole), Zyprexa Relprevv (olanzapine pamoate), and Haldol Decanoate (haloperidol decanoate) [5]. These alternatives offer different mechanisms of action and dosing frequencies, providing various options for patients requiring long-term treatment.